TearClear Appoints Dr. Amir Shojaei Chief Development Officer (BioSpace)

TearClear Appoints Dr. Amir Shojaei Chief Development Officer

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, a global ophthalmic pharmaceutical company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as chief development officer, a major step towards planning and executing multiple clinical development and registration programs.

Over his 23-year career, Dr. Shojaei has focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.

“TearClear is disrupting the way current topical medications are delivered to the ocular surface and the uniqueness of their innovation applies to a large number of existing products within ophthalmology,” Dr. Shojaei said. “For me, it was the novel approach to an existing problem coupled with the broad applicability of their platform that attracted me most.”

Learn more about TearClear Appoints Dr. Amir Shojaei Chief Development Officer.
X